Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025
-
Trump warns Iran blockade could last months, sending oil prices soaring
-
Pistons stay alive, Lakers can't stop Rockets
-
No 'meaningful' shift from social media sites after Australia teen ban: govt report
-
Denmark's Soren Torpegaard Lund to 'stay true' at Eurovision
-
Marathon brothers run Ireland in race to find dementia cure
-
Inoue wary of 'clever' Nakatani in sold-out Tokyo superfight
-
Australian Jewish group warned of 'attack' before Bondi mass shooting: inquiry
-
Mamdani calls on King Charles to return Koh-i-Noor diamond
-
New Zealand mosque killer loses bid to overturn convictions
-
Oil at four-year high, stocks slip after Trump blockade warning
-
Key points from the first global talks on phasing out fossil fuels
-
Mountain festival marks spring arrival high above Tokyo
-
Nations urged to 'go further' as fossil fuel exit talks wrap in Colombia
-
Australia's 'most beautiful' street fed up with viral fame
-
Top-seeded Pistons stay alive in playoffs with Magic win
-
Cuban boy's sporting dreams on hold as surgery backlog grows
-
Bali drowning in trash after landfill closed
-
Australian Jewish group warned of 'terrorist attack' before Bondi shooting: inquiry
-
Finland's Eurovision favourite brings flames and a frantic violin to Vienna
-
ECB set to hold rates despite Iran war energy shock
-
Iran, World Cup loom over FIFA Congress
-
Samsung Electronics posts record quarterly profit on AI boom
-
D4vd used Amazon chainsaws to hack up teen's body: prosecutors
-
Route1 Reports Fiscal Year 2025 Results and Continued Transition Toward Recurring, Lifecycle-Based Revenue
-
InHand Networks FWA12 5G FWA Router: Ideal Connectivity for Multi-Store Retail & Hospitality
-
Meta chief Zuckerberg doubles down on AI spending
-
Saudi to end LIV Golf funding this year: reports
-
Google-parent Alphabet soars as Meta stumbles over AI costs
-
Powell's decision to stay on at Fed ignites new Trump insult
-
Brazil lowers benchmark rate to 14.5% in second consecutive cut
-
'This cannot happen': Arsenal's Arteta livid over Eze penalty review
-
Air quality improving in Europe but more effort needed: report
-
Putin, Trump discuss Iran, Ukraine in phone call: Kremlin
-
Crazy flights: Kiss frontman produces plane disaster movie
-
Google-parent Alphabet soars as rivals stumble over AI costs
-
Romanian behind 'swatting' attacks in US gets four years in prison
-
Arsenal, Atletico trade penalties in Champions League semi-final draw
-
Anti-Bezos campaign urges Met Gala boycott in New York
-
African oil producers defend need to drill at fossil fuel exit talks
-
Iran officials leave Canada before FIFA Congress over airport 'insult': Iranian media
-
Oil spikes while divided Federal Reserve keeps interest rates unchanged
-
Palace boss Glasner eager for another trophy in Europe
-
Alleged Trump assassin took selfie moments before attack: prosecutors
-
Shomrim: the Jewish volunteers protecting their community
-
Powell to bow out as Fed chief but stay as a governor on legal pressure
-
PSG blow as Hakimi ruled out of Champions League semi-final return
-
'Gritty' Philadelphia pitches itself as low-cost US World Cup choice
-
'I literally was a fool': Musk grilled in OpenAI trial
-
OpenAI facing 'waves' of US lawsuits over Canada mass shooting
-
Trump says US has 'a shot' at crewed Moon landing before presidency ends
Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025
HAMILTON, BERMUDA / ACCESS Newswire / August 26, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it will host its Half Year 2025 Financial Results and Business Update Call on Friday, August 29, 2025. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks.
Event: Altamira Therapeutics First Half 2025 Financial Results and Business Update Call
Date: Friday, August 29, 2025
Time: 8:00 am ET
Access:
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 427043
Webcast URL: https://www.webcaster4.com/Webcast/Page/2797/52765
Participants will be greeted by an operator and asked for the access code. If a caller does not have the code, they can reference the company name.
The call will be in listen-only mode.
A replay of the call will be available 30 minutes after the live event via the Investors section of the Altamira website at https://ir.altamiratherapeutics.com/.
Replay access:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 52765
Expiration: Friday, September 12, 2025
About Altamira Therapeutics
Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/
Investor Contact
SOURCE: Altamira Therapeutics
View the original press release on ACCESS Newswire
H.Gonzales--AT
